NEW YORK (GenomeWeb) – Exosome Diagnostics today announced that it has raised $60 million in a Series B round of financing.
Participating investors included Forbion Capital Partners, NGN Capital, and CD Ventures. Qiagen, Arcus Ventures, Tiger Management, and Blue Ridge Capital participated as new investors in the company.
Exosome Diagnostics expects to use the funds to support the growth of its commercial diagnostics, regulatory, and companion diagnostics divisions. In addition, it plans to develop potential new diagnostic tests outside of oncology, such as in neurodegenerative diseases, and expand the development of its protein biomarker programs.
"We are poised to launch the first ever combined RNA plus DNA liquid biopsy based commercial diagnostics tests, as well as potential companion diagnostic programs with pharma, to fully exploit the value of our robust sensitive, liquid biopsy based approach," said President and CEO John Boyce in a statement.
The company also recently announced the launch of its Academic Bench to Clinical Diagnostics free program, which aims to help researchers bring exosome-based biosignature assays to clinical labs.